United Therapeutics Corporation $UTHR Shares Bought by Wealth Enhancement Advisory Services LLC

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR) by 77.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,084 shares of the biotechnology company’s stock after buying an additional 2,655 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in United Therapeutics were worth $1,792,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently added to or reduced their stakes in the company. SVB Wealth LLC acquired a new position in United Therapeutics during the 1st quarter valued at about $32,000. Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the first quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 85 shares during the period. Sound Income Strategies LLC acquired a new position in shares of United Therapeutics in the first quarter valued at about $49,000. Brooklyn Investment Group increased its holdings in shares of United Therapeutics by 103.2% in the first quarter. Brooklyn Investment Group now owns 193 shares of the biotechnology company’s stock valued at $59,000 after purchasing an additional 98 shares during the period. Finally, WPG Advisers LLC acquired a new position in shares of United Therapeutics in the first quarter valued at about $60,000. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, COO Michael Benkowitz sold 22,500 shares of the firm’s stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $417.64, for a total value of $9,396,900.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 21st. The shares were sold at an average price of $308.75, for a total value of $3,396,250.00. Following the completion of the transaction, the executive vice president owned 36,781 shares in the company, valued at approximately $11,356,133.75. This trade represents a 23.02% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 196,935 shares of company stock worth $75,618,342 in the last quarter. 10.30% of the stock is currently owned by company insiders.

United Therapeutics Stock Down 1.9%

Shares of UTHR opened at $424.31 on Tuesday. United Therapeutics Corporation has a 52 week low of $266.98 and a 52 week high of $442.01. The company has a market capitalization of $19.14 billion, a price-to-earnings ratio of 16.56, a PEG ratio of 6.60 and a beta of 0.62. The stock’s 50-day moving average price is $345.52 and its 200-day moving average price is $315.67.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 EPS for the quarter, missing analysts’ consensus estimates of $6.80 by ($0.39). The company had revenue of $798.60 million during the quarter, compared to analysts’ expectations of $802.13 million. United Therapeutics had a return on equity of 18.73% and a net margin of 40.36%.The firm’s quarterly revenue was up 11.7% compared to the same quarter last year. During the same quarter in the previous year, the company earned $5.85 EPS. As a group, equities analysts anticipate that United Therapeutics Corporation will post 24.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on UTHR shares. Wells Fargo & Company increased their price objective on United Therapeutics from $295.00 to $414.00 and gave the company an “equal weight” rating in a report on Wednesday, September 3rd. Oppenheimer increased their price objective on United Therapeutics from $510.00 to $575.00 and gave the company an “outperform” rating in a report on Friday, September 5th. Morgan Stanley cut their price objective on United Therapeutics from $348.00 to $328.00 and set an “equal weight” rating on the stock in a report on Thursday, July 10th. Jefferies Financial Group increased their price objective on United Therapeutics from $432.00 to $564.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. Finally, HC Wainwright increased their price objective on United Therapeutics from $400.00 to $500.00 and gave the company a “buy” rating in a report on Friday, September 5th. Ten analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $449.57.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.